Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab plus low-dose steroids for refractory nephrotic syndrome (prospective cohort)
ChiCTR2100046611Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of Sun Yat-sen University
- Start
- Jan 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of rituximab in nephrosis, focal segmental glomerulosclerosis (FSGS), membranoproliferative glomerulonephritis (MPGN) and 2 more, sponsored by The First Affiliated Hospital of Sun Yat-sen University. Primary endpoint: 24-hour urinary protein quantification. Started Jan 2021; status: recruiting.
02
Drugs
rituximab
03
Conditions
nephrosisfocal segmental glomerulosclerosis (FSGS)membranoproliferative glomerulonephritis (MPGN)IgA nephropathy (IgAN)Complement 3 glomerulopathy (C3G)
Beyond the preview
Go deeper on ChiCTR2100046611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100046611.